Listed

Amneal Pharmaceuticals, Inc.: Form 10-K for the period ended Dec 31, 2022

Filed with the SEC on Mar 3, 2023 and accepted by EDGAR at Mar 3, 2023, 17:08 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2022-01-01 to 2022-12-31$2.21bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue12 months2022-01-01 to 2022-12-31$1.42bnus-gaap:CostOfGoodsAndServicesSold
Gross profit12 months2022-01-01 to 2022-12-31$784.7mus-gaap:GrossProfit
Research and development12 months2022-01-01 to 2022-12-31$195.7mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative12 months2022-01-01 to 2022-12-31$399.7mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income12 months2022-01-01 to 2022-12-31−$94.9mus-gaap:OperatingIncomeLoss
Income tax12 months2022-01-01 to 2022-12-31$6.7mus-gaap:IncomeTaxExpenseBenefit
Net income12 months2022-01-01 to 2022-12-31−$270.6mus-gaap:NetIncomeLoss
Diluted EPS12 months2022-01-01 to 2022-12-31−$0.86us-gaap:EarningsPerShareDiluted
Basic EPS12 months2022-01-01 to 2022-12-31−$0.86us-gaap:EarningsPerShareBasic
Diluted shares (weighted)12 months2022-01-01 to 2022-12-31150,944,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow12 months2022-01-01 to 2022-12-31$65.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2022-01-01 to 2022-12-31$46.4mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2022-12-31$26.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-12-31$1.41bnus-gaap:AssetsCurrent
Total assetsAt period end2022-12-31$3.80bnus-gaap:Assets
Current liabilitiesAt period end2022-12-31$752.8mus-gaap:LiabilitiesCurrent
Long-term debtAt period end2022-12-31$2.59bnus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2022-12-31$30.0mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2022-12-31$298.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001723128-23-000009. Last ingested by Listed: Nov 10, 2026, 02:45 ET. Listed shows no prices and gives no investment advice.